Top

Annals of Surgical Oncology

Published in:

Open Access 01-04-2020 | Colon Cancer | Colorectal Cancer

Beyond the NCCN Risk Factors in Colon Cancer: An Evaluation in a Swedish Population-Based Cohort

Authors: Erik Osterman, MD, Artur Mezheyeuski, MD, PhD, Tobias Sjöblom, MD, PhD, Bengt Glimelius, MD, PhD

Published in: Annals of Surgical Oncology | Issue 4/2020

Abstract

Background

The purpose of this study was to investigate whether pT3–4 and pN-subclassifications, lymph-node ratio (LNR), tumour deposits, pre- and postoperative carcinoembryonic antigen (CEA), and C-reactive protein (CRP)—all parameters commonly collected in clinical management—add information about recurrence risk against a background of routine clinicopathological parameters as defined by the NCCN.

Methods

The prospective cohort consisted of all 416 patients diagnosed with colon cancer stage I–III in Uppsala County between 2010 and 2015. Cox proportional hazard models were used to calculate hazard ratios for time to recurrence and overall survival. The results were compared with the entire Swedish population concerning parameters recorded in the national quality registry, SCRCR, during the same time period.

Results

The Uppsala cohort was representative of the entire Swedish cohort. In unadjusted analyses, pT3-subclassification, pN-subclassification, LNR, tumour deposits, elevated postoperative CEA, and preoperative CRP correlated with recurrence. After adjusting for T-, N-stage, and NCCN risk factors, pN-subclassification, sidedness, and elevated postoperative CEA levels correlated with recurrence. Survival correlated with parameters associated with recurrence, LNR, and elevated postoperative CRP.

Conclusions

Additional information on recurrence risk is available from several routinely recorded parameters, but most of the risk is predicted by the commonly used clinicopathological parameters.

Available only for authorised users

Benson AB, Venook AP, Al-Hawary MM, et al. National comprehensive cancer network. Colon Cancer (Version 2.2019). May 2019. https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf. Accessed 10 June 2019.

Labianca R, Nordlinger B, Beretta GD, et al. Early colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi64-72. https://doi.org/10.1093/annonc/mdt354 CrossRef

Schmoll HJ, Van Cutsem E, Stein A, et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2012;23(10):2479–516. https://doi.org/10.1093/annonc/mds236 CrossRef

Dienstmann R, Salazar R, Tabernero J. Personalizing colon cancer adjuvant therapy: selecting optimal treatments for individual patients. J Clin Oncol. 2015;33(16):1787–96. https://doi.org/10.1200/jco.2014.60.0213 CrossRefPubMed

Petrelli F, Tomasello G, Borgonovo K, et al. Prognostic survival associated with left-sided vs right-sided colon cancer: a systematic review and meta-analysis. JAMA Oncol. 2017;3(2):211–9. https://doi.org/10.1001/jamaoncol.2016.4227 CrossRefPubMed

Missiaglia E, Jacobs B, D’Ario G, et al. Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Ann Oncol Off J Eur Soc Med Oncol. 2014;25(10):1995–2001. https://doi.org/10.1093/annonc/mdu275 CrossRef

Weiss JM, Pfau PR, O’Connor ES, et al. Mortality by stage for right- versus left-sided colon cancer: analysis of surveillance, epidemiology, and end results–Medicare data. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(33):4401–9. https://doi.org/10.1200/jco.2011.36.4414 CrossRef

Huang C-W, Tsai H-L, Huang M-Y, et al. Different clinicopathologic features and favorable outcomes of patients with stage III left-sided colon cancer. World J Surg Oncol. 2015;13:257. https://doi.org/10.1186/s12957-015-0640-4 CrossRefPubMedPubMedCentral

Brungs D, Aghmesheh M, de Souza P, et al. Sidedness is prognostic in locoregional colon cancer: an analysis of 9509 Australian patients. BMC Cancer. 2017;17(1):251. https://doi.org/10.1186/s12885-017-3255-z CrossRefPubMedPubMedCentral

10.

Shin R, Jeong S-Y, Yoo HY, et al. Depth of mesorectal extension has prognostic significance in patients with T3 rectal cancer. Dis Colon Rectum. 2012;55(12):1220–8. https://doi.org/10.1097/dcr.0b013e31826fea6a CrossRef

11.

Akagi Y, Shirouzu K, Kinugasa T. Extramural extension as indicator for postoperative adjuvant chemotherapy in Stage IIA (pT3N0) colon cancer. J Surg Oncol. 2013;108(6):358–63. https://doi.org/10.1002/jso.23407 CrossRefPubMedPubMedCentral

12.

Merkel S, Wein A, Günther K, Papadopoulos T, Hohenberger W, Hermanek P. High-risk groups of patients with Stage II colon carcinoma. Cancer. 2001;92(6):1435–43.CrossRef

13.

Pollheimer MJ, Kornprat P, Pollheimer VS, et al. Clinical significance of pT sub-classification in surgical pathology of colorectal cancer. Int J Colorectal Dis. 2010;25(2):187–96. https://doi.org/10.1007/s00384-009-0801-4 CrossRefPubMed

14.

Jestin P, Påhlman L, Glimelius B, Gunnarsson U. Cancer staging and survival in colon cancer is dependent on the quality of the pathologists’ specimen examination. Eur J Cancer. 2005;41(14):2071–8. https://doi.org/10.1016/j.ejca.2005.06.012 CrossRefPubMed

15.

Zhang M-R, Xie T-H, Chi J-L, et al. Prognostic role of the lymph node ratio in node positive colorectal cancer: a meta-analysis. Oncotarget. 2016;7(45):72898–907. https://doi.org/10.18632/oncotarget.12131 CrossRefPubMedPubMedCentral

16.

Thirunavukarasu P, Talati C, Munjal S, Attwood K, Edge SB, Francescutti V. Effect of incorporation of pretreatment serum carcinoembryonic antigen levels into AJCC staging for colon cancer on 5-year survival. JAMA Surg. 2015;150(8):747–55. https://doi.org/10.1001/jamasurg.2015.0871 CrossRefPubMed

17.

Lin B-R, Lin Y-L, Lai H-S, Lee P-H, Chang K-J, Liang J-T. Overall survival of stage III colon cancer with only one lymph node metastasis is independently predicted by preoperative carcinoembryonic antigen level and lymph node sampling status. PLoS ONE. 2015;10(9). https://doi.org/10.1371/journal.pone.0137053 CrossRefPubMedPubMedCentral

18.

Pathak S, Nunes QM, Daniels IR, Smart NJ. Is C-reactive protein useful in prognostication for colorectal cancer? A systematic review. Colorectal Dis. 2014;16(10):769–76. https://doi.org/10.1111/codi.12700 CrossRefPubMed

19.

Nozoe T, Mori E, Takahashi I, Ezaki T. Preoperative elevation of serum C-reactive protein as an independent prognostic indicator of colorectal carcinoma. Surg Today. 2008;38(7):597–602. https://doi.org/10.1007/s00595-007-3680-8 CrossRefPubMed

20.

McMillan DC, Canna K, McArdle CS. Systemic inflammatory response predicts survival following curative resection of colorectal cancer. Br J Surg. 2003;90(2):215–9. https://doi.org/10.1002/bjs.4038 CrossRefPubMed

21.

Osterman E, Glimelius B. Recurrence risk after up-to-date colon cancer staging, surgery, and pathology: analysis of the entire Swedish population. Dis Colon Rectum. 2018;61(9):1016–25. https://doi.org/10.1097/dcr.0000000000001158 CrossRefPubMed

22.

Nagtegaal ID, Knijn N, Hugen N, et al. Tumor deposits in colorectal cancer: improving the value of modern staging-a systematic review and meta-analysis. J Clin Oncol Off J Am Soc Clin Oncol. 2017;35(10):1119–27. https://doi.org/10.1200/jco.2016.68.9091 CrossRef

23.

Kodeda K, Nathanaelsson L, Jung B, et al. Population-based data from the Swedish Colon Cancer Registry. Br J Surg. 2013;100(8):1100–7. https://doi.org/10.1002/bjs.9166 CrossRefPubMed

24.

SCB statistikdatabasen : [Electronic resource] Statistical database. http://www.statistikdatabasen.scb.se. Accessed 24 March 2019.

25.

Fitz-Henry J. The ASA classification and peri-operative risk. Ann R Coll Surg Engl. 2011;93(3):185–7. https://doi.org/10.1308/rcsann.2011.93.3.185a CrossRefPubMedPubMedCentral

26.

Punt CJA, Buyse M, Köhne C-H, et al. Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials. J Natl Cancer Inst. 2007;99(13):998–1003. https://doi.org/10.1093/jnci/djm024 CrossRefPubMed

27.

Kremers WK. Concordance for survival time data: fixed and time-dependent covariates and possible ties in predictor and time. Tech Rep Ser 80. April 2007:17. https://www.mayo.edu/research/documents/biostat-80pdf/doc-10027891. Accessed 11 June 2019.

28.

Baguena G, Pellino G, Frasson M, et al. Prognostic Impact of pT stage and peritoneal invasion in locally advanced colon cancer. Dis Colon Rectum. March 2019. https://doi.org/10.1097/dcr.0000000000001367 CrossRefPubMed

29.

Benson AB, Venook AP, Al-Hawary MM, et al. NCCN Guidelines insights: colon cancer, Version 2.2018. J Natl Compr Canc Netw. 2018;16(4):359–69. https://doi.org/10.6004/jnccn.2018.0021 CrossRefPubMed

30.

Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12(4):298–306. https://doi.org/10.1038/nrc3245 CrossRefPubMed

31.

Jeffery M, Hickey BE, Hider PN, See AM. Follow-up strategies for patients treated for nonmetastatic colorectal cancer. Cochrane Database Syst Rev. 2016. https://doi.org/10.1002/14651858.cd002200.pub3 CrossRef

Title: Beyond the NCCN Risk Factors in Colon Cancer: An Evaluation in a Swedish Population-Based Cohort
Authors: Erik Osterman, MD
Artur Mezheyeuski, MD, PhD
Tobias Sjöblom, MD, PhD
Bengt Glimelius, MD, PhD
Publication date: 01-04-2020
Publisher: Springer International Publishing
Keywords: Colon Cancer
Colon Cancer
Published in: Annals of Surgical Oncology / Issue 4/2020
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-019-08148-3

2024 ASCO Annual Meeting

Springer Medicine

Beyond the NCCN Risk Factors in Colon Cancer: An Evaluation in a Swedish Population-Based Cohort

Abstract

Background

Methods

Results

Conclusions

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2020

Pain Control in Breast Surgery: Survey of Current Practice and Recommendations for Optimizing Management—American Society of Breast Surgeons Opioid/Pain Control Workgroup

Differences in Metastatic Pattern in Patients Presenting With or Without Obstructing Colorectal Cancer: A Retrospective Observational Study of 2595 Patients

Treatment and Prognosis of Radiation-Associated Breast Angiosarcoma in a Nationwide Population

Incidental Gallbladder Cancer: Permission to Operate